Which has stronger valuation and earnings, TKNO or EVMN?

Alpha Teknova has higher revenue and earnings than Evommune. Alpha Teknova is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Teknova $40.52M 6.79 -$17.26M -$0.32 N/A Evommune $13M 54.82 -$68.87M -$9.50 N/A

Alpha Teknova (TKNO) Competitors

$5.13 -0.05 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$5.12 0.00 (-0.10%)

As of 04:27 PM Eastern

Compare

TKNO vs. EVMN, DRUG, LBRX, AMPH, and ESPR

Should you buy Alpha Teknova stock or one of its competitors? MarketBeat compares Alpha Teknova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Teknova include Evommune (EVMN), Bright Minds Biosciences (DRUG), LB Pharmaceuticals (LBRX), Amphastar Pharmaceuticals (AMPH), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.

How does Alpha Teknova compare to Evommune?

Alpha Teknova (NASDAQ:TKNO) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Alpha Teknova has higher revenue and earnings than Evommune. Alpha Teknova is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	6.79	-$17.26M	-$0.32	N/A
Evommune	$13M	54.82	-$68.87M	-$9.50	N/A

Evommune has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Evommune's return on equity of 0.00% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
Evommune	N/A	N/A	N/A

13.8% of Alpha Teknova shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Evommune had 17 more articles in the media than Alpha Teknova. MarketBeat recorded 18 mentions for Evommune and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Evommune's score of 0.08 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Teknova	Very Positive
Evommune	Neutral

Alpha Teknova presently has a consensus price target of $8.00, indicating a potential upside of 55.95%. Evommune has a consensus price target of $49.25, indicating a potential upside of 148.94%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Evommune beats Alpha Teknova on 10 of the 16 factors compared between the two stocks.

How does Alpha Teknova compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Bright Minds Biosciences has higher earnings, but lower revenue than Alpha Teknova. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Alpha Teknova	$40.52M	6.79	-$17.26M	-$0.32	N/A

Bright Minds Biosciences presently has a consensus target price of $143.83, indicating a potential upside of 93.27%. Alpha Teknova has a consensus target price of $8.00, indicating a potential upside of 55.95%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Bright Minds Biosciences is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Bright Minds Biosciences has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Bright Minds Biosciences' return on equity of -20.58% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Alpha Teknova	-41.07%	-24.32%	-16.34%

In the previous week, Bright Minds Biosciences had 12 more articles in the media than Alpha Teknova. MarketBeat recorded 13 mentions for Bright Minds Biosciences and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Bright Minds Biosciences' score of 0.29 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Overall Sentiment
Bright Minds Biosciences	Neutral
Alpha Teknova	Very Positive

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 12.5% of Alpha Teknova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bright Minds Biosciences has a beta of -5.53, indicating that its stock price is 653% less volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Summary

Bright Minds Biosciences beats Alpha Teknova on 9 of the 16 factors compared between the two stocks.

How does Alpha Teknova compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Alpha Teknova has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Alpha Teknova	$40.52M	6.79	-$17.26M	-$0.32	N/A

LB Pharmaceuticals presently has a consensus price target of $38.40, suggesting a potential upside of 37.39%. Alpha Teknova has a consensus price target of $8.00, suggesting a potential upside of 55.95%. Given Alpha Teknova's higher possible upside, analysts plainly believe Alpha Teknova is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

LB Pharmaceuticals has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. LB Pharmaceuticals' return on equity of 0.00% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Alpha Teknova	-41.07%	-24.32%	-16.34%

In the previous week, LB Pharmaceuticals had 9 more articles in the media than Alpha Teknova. MarketBeat recorded 10 mentions for LB Pharmaceuticals and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat LB Pharmaceuticals' score of 0.49 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Overall Sentiment
LB Pharmaceuticals	Neutral
Alpha Teknova	Very Positive

13.8% of Alpha Teknova shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Alpha Teknova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Alpha Teknova beats LB Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Alpha Teknova compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Amphastar Pharmaceuticals has higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.11	$98.09M	$1.66	10.90
Alpha Teknova	$40.52M	6.79	-$17.26M	-$0.32	N/A

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Alpha Teknova's net margin of -41.07%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Alpha Teknova	-41.07%	-24.32%	-16.34%

Amphastar Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Alpha Teknova. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Amphastar Pharmaceuticals' score of 0.19 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Overall Sentiment
Amphastar Pharmaceuticals	Neutral
Alpha Teknova	Very Positive

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Alpha Teknova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals currently has a consensus target price of $24.00, suggesting a potential upside of 32.64%. Alpha Teknova has a consensus target price of $8.00, suggesting a potential upside of 55.95%. Given Alpha Teknova's stronger consensus rating and higher possible upside, analysts plainly believe Alpha Teknova is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Amphastar Pharmaceuticals beats Alpha Teknova on 11 of the 16 factors compared between the two stocks.

How does Alpha Teknova compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Alpha Teknova's net margin of -41.07%. Esperion Therapeutics' return on equity of -0.14% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Alpha Teknova	-41.07%	-24.32%	-16.34%

In the previous week, Esperion Therapeutics and Esperion Therapeutics both had 1 articles in the media. Alpha Teknova's average media sentiment score of 1.89 beat Esperion Therapeutics' score of 0.96 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Overall Sentiment
Esperion Therapeutics	Positive
Alpha Teknova	Very Positive

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by insiders. Comparatively, 12.5% of Alpha Teknova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alpha Teknova has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A
Alpha Teknova	$40.52M	6.79	-$17.26M	-$0.32	N/A

Esperion Therapeutics presently has a consensus price target of $5.54, indicating a potential upside of 76.43%. Alpha Teknova has a consensus price target of $8.00, indicating a potential upside of 55.95%. Given Esperion Therapeutics' higher probable upside, equities research analysts plainly believe Esperion Therapeutics is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Esperion Therapeutics beats Alpha Teknova on 9 of the 16 factors compared between the two stocks.

Get Alpha Teknova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TKNO vs. The Competition

Export

Metric	Alpha Teknova	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$277.72M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-16.03	17.78	22.39	24.18
Price / Sales	6.79	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	4.01	6.63	9.84	6.72
Net Income	-$17.26M	$24.20M	$3.57B	$337.19M
7 Day Performance	28.25%	-3.24%	-1.16%	0.48%
1 Month Performance	50.88%	0.53%	3.85%	5.07%
1 Year Performance	-10.78%	47.24%	27.40%	34.25%

Alpha Teknova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TKNO Alpha Teknova	3.1209 of 5 stars	$5.13 -1.0%	$8.00 +55.9%	-9.6%	$277.72M	$40.52M	N/A	240	Positive News
EVMN Evommune	3.0571 of 5 stars	$23.29 +1.8%	$49.25 +111.5%	N/A	$823.74M	$13M	N/A	45	News Coverage Insider Trade
DRUG Bright Minds Biosciences	3.1327 of 5 stars	$86.28 +3.3%	$143.83 +66.7%	+171.1%	$812.64M	N/A	N/A	N/A	Trending News Analyst Forecast Analyst Revision
LBRX LB Pharmaceuticals	1.9018 of 5 stars	$28.33 +0.7%	$38.40 +35.5%	N/A	$812.42M	N/A	N/A	16
AMPH Amphastar Pharmaceuticals	3.9753 of 5 stars	$18.81 +2.2%	$24.50 +30.2%	-27.3%	$811.75M	$720.53M	11.33	1,976	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TKNO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Teknova (TKNO) Competitors

TKNO vs. EVMN, DRUG, LBRX, AMPH, and ESPR

How does Alpha Teknova compare to Evommune?

Summary

How does Alpha Teknova compare to Bright Minds Biosciences?

Summary

How does Alpha Teknova compare to LB Pharmaceuticals?

Summary

How does Alpha Teknova compare to Amphastar Pharmaceuticals?

Summary

How does Alpha Teknova compare to Esperion Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TKNO vs. The Competition

Alpha Teknova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Teknova (TKNO) Competitors

TKNO vs. EVMN, DRUG, LBRX, AMPH, and ESPR

How does Alpha Teknova compare to Evommune?

Which has stronger valuation and earnings, TKNO or EVMN?

Is TKNO or EVMN more profitable?

Do institutionals & insiders have more ownership in TKNO or EVMN?

Does the media refer more to TKNO or EVMN?

Do analysts rate TKNO or EVMN?

Summary

How does Alpha Teknova compare to Bright Minds Biosciences?

Which has higher earnings and valuation, DRUG or TKNO?

Do analysts recommend DRUG or TKNO?

Is DRUG or TKNO more profitable?

Does the media refer more to DRUG or TKNO?

Do insiders & institutionals have more ownership in DRUG or TKNO?

Which has more volatility and risk, DRUG or TKNO?

Summary

How does Alpha Teknova compare to LB Pharmaceuticals?

Which has higher valuation & earnings, LBRX or TKNO?

Do analysts recommend LBRX or TKNO?

Is LBRX or TKNO more profitable?

Does the media prefer LBRX or TKNO?

Do institutionals and insiders believe in LBRX or TKNO?

Summary

How does Alpha Teknova compare to Amphastar Pharmaceuticals?

Which has better valuation and earnings, AMPH or TKNO?

Is AMPH or TKNO more profitable?

Which has more volatility and risk, AMPH or TKNO?

Does the media prefer AMPH or TKNO?

Do institutionals & insiders have more ownership in AMPH or TKNO?

Do analysts rate AMPH or TKNO?

Summary

How does Alpha Teknova compare to Esperion Therapeutics?

Which has more risk & volatility, ESPR or TKNO?

Is ESPR or TKNO more profitable?

Does the media prefer ESPR or TKNO?

Do insiders & institutionals believe in ESPR or TKNO?

Which has higher valuation & earnings, ESPR or TKNO?

Do analysts rate ESPR or TKNO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TKNO vs. The Competition

Alpha Teknova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools